Dr. Paul Sorajja presents Tripair™ at TCT San Francisco

Leading interventional cardiologist, Dr. Paul Sorajja, will present  Tripair™, Coramaze’s innovative transcatheter therapy for tricuspid repair, at the Cardiovascular Research Foundation’s TCT meeting in San Francisco this week.

During the innovation session, Dr. Sorajja will explain that Tripair™ is designed to overcome the anatomical and operational complexities that leave behind 75% of current tricuspid regurgitation patients.

Tripair™ brings what the company terms an “enabling simplicity” an enabling simplicity to address the current complexities. First-in-human data shows it to be simple, safe and efficient with median deployment times of 30 minutes, a novel self-centering approach and full retrievability.

The company’s leadership team will be in San Francisco to connect with physicians, innovators, and industry leaders, and to exchange insights on how Tripair™ can contribute to advancing care for patients worldwide.

Where to find Coramaze at TCT:
TCT San Francisco – Innovation Theater, Hall E, Moscone Center
Monday, October 27 | 3:40 PM – 4:48 PM PDT
Tripair™ Presentation at 4:28 PM
Session: Innovations in Transcatheter Tricuspid Valve Repair
Presenter: Paul Sorajja, MD